Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling

Biochemical Journal

Volumn 434, Issue 3, 2011, Pages 493-501

  Shum, Ka To ^a   Chan, Celine ^a   Leung, Ching Man ^a   Tanner, Julian A ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

G quadruplex; Isothermal titration calorimetry (ITC); Sclerosteosis; Sclerostin; Systematic evolution of ligands by exponential enrichment (SELEX); Wnt signalling

Indexed keywords

APTAMER; COMPLEMENTARY DNA; GLUTATHIONE; LIGAND; SCLEROSTIN; SINGLE STRANDED DNA; WNT PROTEIN;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; ASSAY; CELL CULTURE; ISOTHERMAL TITRATION CALORIMETRY; MAMMAL CELL; MOLECULAR CLONING; NONHUMAN; OSTEOPOROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT;

3T3 CELLS; ANIMALS; APTAMERS, NUCLEOTIDE; BONE MORPHOGENETIC PROTEINS; CALORIMETRY; CIRCULAR DICHROISM; GENETIC MARKERS; GLYCOPROTEINS; MICE; PROTEIN BINDING; SIGNAL TRANSDUCTION; THERMODYNAMICS; WNT PROTEINS;

EID: 79952159933     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20101096     Document Type: Article

References (39)

1. Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Lacza, C., Wuyts, W., Van Den Ende, J., Willems, P. et al. (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537-543
2. Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y. et al. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577-589
3. Hamersma, H., Gardner, J. and Beighton, P. (2003) The natural history of sclerosteosis. Clin. Genet. 63, 192-197
4. Piters, E., Culha, C., Moester, M., Van Bezooijen, R., Adriaensen, D., Mueller, T., Weidauer, S., Jennes, K., De Freitas, F., Lowik, C. et al. (2010) First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum. Mutat. 31, E1526-E1543
5. Paszty, C., Turner, C. H. and Robinson, M. K. (2010) Sclerostin: a gem from the genome leads to bone-building antibodies. J. Bone Miner. Res. 25, 1897-1904
6. Agholme, F., Li, X., Isaksson, H., Ke, H. Z. and Aspenberg, P. (2010) Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J. Bone Miner. Res. 25, 2412-2418
7. Padhi, D., Jang, G., Stouch, B., Fang, L. and Posvar, E. (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19-26
8. Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K., Moore, A., Zhang, L. et al. (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890-10900
9. Van Bezooijen, R. L., Papapoulos, S. E. and Lowik, C. W. (2005) Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J. Endocrinol. Invest. 28, 15-17
10. Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling-Hampton, K. et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267-6276 (Pubitemid 37522584)
11. Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E. and Wu, D. (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883-19887
12. Kamiya, N., Ye, L., Kobayashi, T., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q. and Mishina, Y. (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135, 3801-3811
13. Ten Dijke, P., Krause, C., De Gorter, D. J., Lowik, C. W. and Van Bezooijen, R. L. (2008) Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Joint Surg. Am. 90 (Suppl. 1), 31-35
14. Van Bezooijen, R. L., Roelen, B. A., Visser, A., Van Der Wee-Pals, L., De Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., Ten Dijke, P. and Lowik, C. W. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805-814
15. Semenov, M., Tamai, K. and He, X. (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770-26775
16. Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D. et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-523 (Pubitemid 33152786)
17. Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K. and Lifton, R. P. (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521
18. Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R. et al. (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578-588
19. Eddleston, A., Marenzana, M., Moore, A. R., Stephens, P., Muzylak, M., Marshall, D. and Robinson, M. K. (2009) A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J. Bone Miner. Res. 24, 1662-1671
20. Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K. et al. (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res. 25, 948-959
21. Tian, X., Setterberg, R. B., Li, X., Paszty, C., Ke, H. Z. and Jee, W. S. (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47, 529-533
22. Reference deleted
23. Reference deleted
24. Rey, J. P. and Ellies, D. L. (2010) Wnt modulators in the biotech pipeline. Dev. Dyn. 239, 102-114
25. Keefe, A. D., Pai, S. and Ellington, A. (2010) Aptamers as therapeutics. Nat. Rev. Drug Discovery 9, 537-550
26. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510
27. Ellington, A. D. and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822
28. Que-Gewirth, N. S. and Sullenger, B. A. (2007) Gene therapy progress and prospects: RNA aptamers. Gene Ther. 14, 283-291
29. Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L. and Janjic, N. (1998) 2′- Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556-20567
30. Shum, K. T. and Tanner, J. A. (2008) Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. ChemBioChem 9, 3037-3045
31. Murphy, M. B., Fuller, S. T., Richardson, P. M. and Doyle, S. A. (2003) An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Res. 31, e110
32. Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R. et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948 (Pubitemid 350162903)
33. Choi, M. Y., Chan, C. C., Chan, D., Luk, K. D., Cheah, K. S. and Tanner, J. A. (2009) Biochemical consequences of sedlin mutations that cause spondyloepiphyseal dysplasia tarda. Biochem. J. 423, 233-242
34. Shafer, R. H. and Smirnov, I. (2000) Biological aspects of DNA/RNA quadruplexes. Biopolymers 56, 209-227 (Pubitemid 33115752)
35. Burge, S., Parkinson, G. N., Hazel, P., Todd, A. K. and Neidle, S. (2006) Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res. 34, 5402-5415 (Pubitemid 44742430)
36. Weidauer, S. E., Schmieder, P., Beerbaum, M., Schmitz, W., Oschkinat, H. and Mueller, T. D. (2009) NMR structure of the Wnt modulator protein sclerostin. Biochem. Biophys. Res. Commun. 380, 160-165
37. Craig, T. A., Sommer, S. L., Beito, T. G. and Kumar, R. (2009) Production and characterization of monoclonal antibodies to human sclerostin. Hybridoma 28, 377-381
38. Oney, S., Lam, R. T., Bompiani, K. M., Blake, C. M., Quick, G., Heidel, J. D., Liu, J. Y., Mack, B. C., Davis, M. E., Leong, K. W. and Sullenger, B. A. (2009) Development of universal antidotes to control aptamer activity. Nat. Med. 15, 1224-1228
39. Rusconi, C. P., Roberts, J. D., Pitoc, G. A., Nimjee, S. M., White, R. R., Quick, Jr, G., Scardino, E., Fay, W. P. and Sullenger, B. A. (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat. Biotechnol. 22, 1423-1428